% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Barthel:916864,
      author       = {Barthel, Henryk and Villemagne, Victor L. and Drzezga,
                      Alexander},
      title        = {{F}uture {D}irections in {M}olecular {I}maging of
                      {N}eurodegenerative {D}isorders},
      journal      = {Journal of nuclear medicine},
      volume       = {63},
      number       = {Supplement 1},
      issn         = {0097-9058},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {FZJ-2023-00156},
      pages        = {68S - 74S},
      year         = {2022},
      abstract     = {The improvement of existing techniques and the development
                      of new molecular imaging methods are an exciting and rapidly
                      developing field in clinical care and research of
                      neurodegenerative disorders. In the clinic, molecular
                      imaging has the potential to improve early and differential
                      diagnosis and to stratify and monitor therapy in these
                      disorders. Meanwhile, in research, these techniques improve
                      our understanding of the underlying pathophysiology and
                      pathobiochemistry of these disorders and allow for drug
                      testing. This article is an overview on our perspective on
                      future developments in neurodegeneration tracers and the
                      associated imaging technologies. For example, we predict
                      that the current portfolio of β-amyloid and tau aggregate
                      tracers will be improved and supplemented by tracers
                      allowing imaging of other protein aggregation pathologies,
                      such as α-synuclein and transactive response DNA binding
                      protein 43 kDa. Future developments will likely also be
                      observed in imaging neurotransmitter systems. This refers to
                      both offering imaging to a broader population in cases
                      involving the dopaminergic, cholinergic, and serotonergic
                      systems and making possible the imaging of systems not yet
                      explored, such as the glutamate and opioid systems. Tracers
                      will be complemented by improved tracers of
                      neuroinflammation and synaptic density. Technologywise, the
                      use of hybrid PET/MRI, dedicated brain PET, and total-body
                      PET scanners, as well as advanced image acquisition and
                      processing protocols, will open doors toward broader and
                      more efficient clinical use and novel research applications.
                      Molecular imaging has the potential of becoming a standard
                      and essential clinical and research tool to diagnose and
                      study neurodegenerative disorders and to guide treatments.
                      On that road, we will need to redefine the role of molecular
                      imaging in relation to that of emerging blood-based
                      biomarkers. Taken together, the unique features of molecular
                      imaging-that is, the potential to provide direct noninvasive
                      information on the presence, extent, localization, and
                      quantity of molecular pathologic processes in the living
                      body-together with the predicted novel tracer and imaging
                      technology developments, provide optimism about a bright
                      future for this approach to improved care and research on
                      neurodegenerative disorders.},
      cin          = {INM-2},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-2-20090406},
      pnm          = {5253 - Neuroimaging (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5253},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {35649650},
      UT           = {WOS:000807305900010},
      doi          = {10.2967/jnumed.121.263202},
      url          = {https://juser.fz-juelich.de/record/916864},
}